Aleix Prat Selected Research

Phenobarbital (Luminal)

1/2022	High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
2/2021	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer.
1/2021	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.
11/2020	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial.
1/2020	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
1/2020	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.
1/2020	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
10/2019	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
1/2019	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
1/2019	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aleix Prat Research Topics

Disease

120	Breast Neoplasms (Breast Cancer) 05/2022 - 06/2007
104	Neoplasms (Cancer) 05/2022 - 06/2007
19	Triple Negative Breast Neoplasms 11/2022 - 04/2012
14	Neoplasm Metastasis (Metastasis) 10/2021 - 11/2007
9	COVID-19 01/2022 - 07/2020
7	Prostatic Neoplasms (Prostate Cancer) 10/2021 - 04/2014
7	Pathologic Complete Response 10/2021 - 09/2013
6	Disease Progression 01/2022 - 05/2008
5	Melanoma (Melanoma, Malignant) 08/2020 - 01/2016
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 11/2009
3	Hypoxia (Hypoxemia) 06/2021 - 04/2012
3	Residual Neoplasm 08/2020 - 01/2019
3	Lung Neoplasms (Lung Cancer) 04/2020 - 12/2013
3	Carcinoma (Carcinomatosis) 01/2018 - 12/2013
2	Neutropenia 01/2021 - 01/2020
2	Death (Near-Death Experience) 01/2021 - 01/2018
2	Circulating Neoplastic Cells 01/2020 - 01/2020
2	Exanthema (Rash) 01/2019 - 11/2009
2	Colorectal Neoplasms (Colorectal Cancer) 12/2017 - 02/2016
2	Glioblastoma (Glioblastoma Multiforme) 11/2017 - 02/2012
2	Colitis 01/2016 - 01/2016
2	Brain Neoplasms (Brain Tumor) 08/2014 - 01/2011
2	Carcinogenesis 05/2014 - 04/2014
2	Ductal Carcinoma 01/2010 - 05/2008
1	Pneumonia (Pneumonitis) 01/2022

Drug/Important Bio-Agent (IBA)

41	Phenobarbital (Luminal)FDA Link 01/2022 - 01/2010
40	Hormones (Hormone)IBA 01/2022 - 09/2008
27	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2009
21	Trastuzumab (Herceptin)FDA Link 10/2021 - 05/2008
18	Biological ProductsIBA 01/2022 - 01/2010
14	Estrogen ReceptorsIBA 01/2020 - 01/2010
14	ClaudinsIBA 12/2015 - 01/2010
11	Pharmaceutical PreparationsIBA 01/2022 - 06/2007
11	human ERBB2 proteinIBA 01/2022 - 09/2008
10	RNA (Ribonucleic Acid)IBA 02/2021 - 09/2013
9	DNA (Deoxyribonucleic Acid)IBA 10/2021 - 04/2012
8	ErbB Receptors (EGF Receptor)IBA 01/2021 - 09/2008
8	Lapatinib (GW572016)FDA Link 01/2021 - 02/2014
8	Docetaxel (Taxotere)FDA Link 10/2019 - 11/2016
7	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
7	Messenger RNA (mRNA)IBA 01/2022 - 09/2015
7	Taxoids (Taxanes)IBA 10/2021 - 11/2016
7	taxaneIBA 11/2020 - 09/2013
6	AnthracyclinesIBA 11/2020 - 04/2013
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2013
5	Fulvestrant (Faslodex)FDA Link 01/2021 - 10/2013
5	ParaffinIBA 07/2020 - 01/2014
5	Formaldehyde (Formol)FDA Link 07/2020 - 01/2014
5	Letrozole (Femara)FDA LinkGeneric 01/2020 - 06/2011
5	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 01/2010
4	pertuzumabIBA 10/2021 - 01/2019
4	Androgen Receptors (Androgen Receptor)IBA 10/2021 - 04/2014
4	AlpelisibIBA 01/2021 - 04/2015
4	exemestane (Aromasin)FDA Link 01/2021 - 06/2011
4	Carboplatin (JM8)FDA LinkGeneric 01/2020 - 02/2017
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 04/2013
4	Phosphotransferases (Kinase)IBA 01/2018 - 10/2013
3	eribulin FDA Link 11/2021 - 01/2021
3	Immunoconjugates (Immunoconjugate)IBA 10/2021 - 01/2021
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2021 - 11/2012
3	pembrolizumabIBA 01/2021 - 01/2016
3	Everolimus FDA Link 01/2021 - 01/2019
3	Estrogens (Estrogen)FDA Link 01/2019 - 09/2008
3	Interleukin-11 (Interleukin 11)IBA 02/2017 - 01/2013
3	IpilimumabIBA 12/2016 - 01/2016
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 10/2016
2	trastuzumab deruxtecanIBA 01/2022 - 10/2021
2	Oxygen (Dioxygen)IBA 01/2022 - 01/2022
2	Ado-Trastuzumab EmtansineIBA 10/2021 - 07/2020
2	Anastrozole (Arimidex)FDA LinkGeneric 02/2021 - 06/2011
2	Tamoxifen FDA LinkGeneric 02/2021 - 01/2013
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 10/2016
2	ribociclibIBA 01/2021 - 01/2020
2	Aromatase InhibitorsIBA 01/2021 - 06/2011
2	atezolizumabIBA 01/2021 - 08/2020
2	Antiviral Agents (Antivirals)IBA 01/2021 - 01/2021
2	CytokinesIBA 01/2021 - 10/2016
2	palbociclibIBA 01/2021 - 11/2020
2	NVP-BKM120IBA 11/2020 - 11/2012
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 11/2020 - 01/2020
2	LigandsIBA 01/2020 - 10/2013
2	olaparibIBA 12/2019 - 11/2012
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018 - 01/2017
2	MicroRNAs (MicroRNA)IBA 02/2017 - 01/2013
2	Programmed Cell Death 1 ReceptorIBA 01/2017 - 01/2016
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 04/2015 - 01/2011
2	Irinotecan (Camptosar)FDA LinkGeneric 08/2014 - 04/2012
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014 - 09/2008
2	Epithelial Cell Adhesion MoleculeIBA 08/2013 - 02/2012
1	COVID-19 VaccinesIBA 01/2022

Therapy/Procedure

80	Therapeutics 01/2022 - 06/2007
33	Drug Therapy (Chemotherapy) 11/2022 - 06/2007
12	Neoadjuvant Therapy 11/2022 - 12/2015
6	Castration 10/2021 - 11/2016
5	Immunotherapy 05/2022 - 01/2020
3	Radiotherapy 01/2018 - 06/2007
2	Palliative Care (Palliative Therapy) 01/2021 - 01/2018
2	Adjuvant Chemotherapy 01/2018 - 01/2016
1	Oncolytic Virotherapy 05/2022
1	Continuity of Patient Care 01/2022